Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study

BACKGROUND: Temsirolimus is an mTOR inhibitor with single-agent antitumor activity in patients with mantle cell lymphoma (MCL). We therefore tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with relapsed or refractory MCL. METHODS: Patients received temsirol...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ansell, Stephen M., Tang, Hui, Kurtin, Paul J., Koenig, Patricia A., Inwards, David J., Shah, Keith, Ziesmer, Steven C., Feldman, Andrew L., Rao, Radha, Gupta, Mamta, Erlichman, Charles, Witzig, Thomas E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3106222/
https://ncbi.nlm.nih.gov/pubmed/21440503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70062-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller